The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Structural basis of PROTAC cooperative recognition for selective protein degradation
Open accessAbstract
Inducing macromolecular interactions with small molecules to activate cellular signaling is a challenging goal. PROTACs (proteolysis-targeting chimeras) are bifunctional molecules that recruit a target protein in proximity to an E3 ubiquitin ligase to trigger protein degradation. Structural elucidation of the key ternary ligase-PROTAC-target species and its impact on target degradation selectivity remain elusive. We solved the crystal structure of Brd4 degrader MZ1 in complex with human VHL and the Brd4 bromodomain (Brd4 BD2). The ligand folds into itself to allow formation of specific intermolecular interactions in the ternary complex. Isothermal titration calorimetry studies, supported by surface mutagenesis and proximity assays, are consistent with pronounced cooperative formation of ternary complexes with Brd4 BD2. Structure-based-designed compound AT1 exhibits highly selective depletion of Brd4 in cells. Our results elucidate how PROTAC-induced de novo contacts dictate preferential recruitment of a target protein into a stable and cooperative complex with an E3 ligase for selective degradation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“By contrast, the cooperativity of a bifunctional proximity inducer system is attributable to the ligand-induced protein–protein interface37.”
From Defining molecular glues with a dual-nanobody cannabidiol sensor (2022) · cites this paper as [37]
In the citing paper
“In previous studies of bifunctional proximity inducers, a cooperativity term (represented by α) has been used to characterize the effects of protein–protein interaction in ternary complex formation36,37.”
From Defining molecular glues with a dual-nanobody cannabidiol sensor (2022) · cites this paper as [37]
In the citing paper
“When plotted on a logarithmic scale, the MG dose-response curve has a familiar sigmoid shape (Fig. 7c), which is in stark contrast to the bell-shaped dose-response curve produced by the bifunctional proximity inducers36,37.”
From Defining molecular glues with a dual-nanobody cannabidiol sensor (2022) · cites this paper as [37]
In the citing paper
“Several mechanisms have been shown to contribute to this increase in selectivity. This includes steric incapability of some targets to form a productive ternary complex, or lack of a suitably positioned lysine residue for ubiquitination.62−69”
From Advancing Targeted Protein Degradation via Multiomics Profiling and Artificial Intelligence (2023) · cites this paper as [63]
In the citing paper
“It is widely believed that degraders uncouple efficacy from target occupancy (Gadd et al., 2017; Nowak et al., 2018; Olson et al., 2018; Roy et al., 2019).”
From Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development (2020) · cites this paper as Gadd et al., 2017
In the citing paper
“An essential step in targeted protein degradation is the drug-induced formation of a ternary complex10,43.”
From Functional E3 ligase hotspots and resistance mechanisms to small-molecule degraders (2023) · cites this paper as [10]
In the citing paper
“While there have been several published crystal structures of ternary complexes 35, 52, 54, there are not yet enough to allow for a thorough and rigorous evaluation of our method.”
From Rationalizing PROTAC-Mediated Ternary Complex Formation Using Rosetta (2021) · cites this paper as [52]
In the citing paper
“The observation that many effective PROTACs exhibit cooperativity in assembling the components of the ternary complex 35, 52, 53 implies the presence of adventitious favorable interactions between the target protein and the E3 ligase in the ternary complex.”
From Rationalizing PROTAC-Mediated Ternary Complex Formation Using Rosetta (2021) · cites this paper as [52]
In the citing paper
“Cooperativity plays a role in the efficiency of the VHL–BRD4 degrader MZ1 (ref.129), but is dispensable for CRBN–BRD4 degraders130.”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [129]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
VMD: visual molecular dynamics
Humphrey, W., Dalke, A., & Schulten, K. (1996) · Journal of Molecular Graphics · doi:10.1016/0263-7855(96)00018-5 · Cited by 66,952
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
Scalable molecular dynamics with NAMD
Phillips, J. C., Braun, R., Wang, W., Gumbart, J., Tajkhorshid, E., Villa, E., Chipot, C., Skeel, R. D., Kalé, L., & Schulten, K. (2005) · Journal of Computational Chemistry · doi:10.1002/jcc.20289 · Cited by 16,914
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463
MolProbity : all-atom structure validation for macromolecular crystallography
Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S., & Richardson, D. C. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909042073 · Cited by 14,115
Overview of the CCP 4 suite and current developments
Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G. W., McCoy, A., et al. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910045749 · Cited by 12,353
Inference of Macromolecular Assemblies from Crystalline State
Krissinel, E., & Henrick, K. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.05.022 · Cited by 10,007
CHARMM: The biomolecular simulation program
Brooks, B. R., Brooks, C. L., MacKerell, A. D., Nilsson, L., Petrella, R. J., Roux, B., Won, Y., Archontis, G., Bartels, C., Boresch, S., et al. (2009) · Journal of Computational Chemistry · doi:10.1002/jcc.21287 · Cited by 9,115
REFMAC 5 for the refinement of macromolecular crystal structures
Murshudov, G. N., Skubák, P., Lebedev, A. A., Pannu, N. S., Steiner, R. A., Nicholls, R. A., Winn, M., Long, F., & Vagin, A. A. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444911001314 · Cited by 8,415
Cited by
Sorted by citations
Items 801–900 of 1,001
Ciulli, A., & Hsia, O. (2022) · Wiley eBooks · doi:10.1002/9781119774198.ch9 · Cited by 8
Self-citationGargano, D., Segatto, M., & Bartolomeo, S. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065665 · Cited by 9
The rise of targeting chimeras (TACs): next-generation medicines that preempt cellular events
Hollingsworth, S. A., Johnson, S. A., Khakbaz, P., Meng, Y., Mouchlis, V. D., Pierce, O., Prytkova, V. D., Vik, E. S., Weiss, D. R., & Shanmugasundaram, V. (2023) · Medicinal Chemistry Research · doi:10.1007/s00044-023-03104-z · Cited by 11
Qiang, Y., Fan, J., Xie, C., Yan, L., Song, X., Zhang, N., Lin, Y., Xiong, J., Zhang, W., Liu, Y., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-2888 · Cited by 8
Tomoshige, S., & Ishikawa, M. (2020) · Angewandte Chemie · doi:10.1002/ange.202004746 · Cited by 8
Reviewing the toolbox for degrader development in oncology
Cresser-Brown, J. O., Marsh, G. P., & Maple, H. J. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.04.009 · Cited by 8
Development of Protein Knockdown Technology as Emerging Drug Discovery Strategy
Ohoka, N. (2018) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.18-00113 · Cited by 8
Julio, A. R., Shikwana, F., Truong, C. C., Burton, N. R., Dominguez, E. R., Turmon, A. C., Cao, J. X., & Backus, K. M. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.30.564067 · Cited by 8
Cheng, H., Chen, L., & Huang, C. (2025) · Oncology Letters · doi:10.3892/ol.2025.14881 · Cited by 7
Discovery of PZ671, a highly potent and in vivo active CRBN-recruiting Bcl-xL degrader
Zhang, P., Thummuri, D., Hu, W., Khan, S. U., He, Y., Zhang, X., Pal, P., Lv, D., Zhou, D., & Zheng, G. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00119f · Cited by 7
The ubiquitin code of RAS proteins: Decoding its role in cancer progression
Shi, Y., Shen, Y., Zhang, X., Zhu, N. W., Ding, Y., Yuan, Y., & Wang, J. (2025) · iScience · doi:10.1016/j.isci.2025.113029 · Cited by 7
Zhang, L., Wang, Q., Li, X., Cheng, X., Cai, L., Guo, A., Zhang, L., Hu, H., Wu, M., Li, X., et al. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5c00473 · Cited by 7
Deng, L., Tian, E., Ma, T., Liang, S., Hu, S., Li, L., & Li, J. (2025) · Results in Chemistry · doi:10.1016/j.rechem.2025.102670 · Cited by 7
Determination of key functional structures of an amorphous VHL-based SMARCA2 PROTAC
Torodii, D., Holmes, J. B., Cordova, M., Moutzouri, P., van Beek, L., Edfeldt, F., Malmerberg, E., Friis, S. D., Johansson, J. R., Milbradt, A. G., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-65478-5 · Cited by 7
Opportunities and challenges of PROTAC in the treatment of protein-driven diseases
Zhou, Z., Liu, P., Li, Y., Liu, X., & Li, J. (2026) · Results in Chemistry · doi:10.1016/j.rechem.2026.103234 · Cited by 7
Riepenhausen, L., Sarnow, A., Robaa, D., & Sippl, W. (2026) · Archiv der Pharmazie · doi:10.1002/ardp.70225 · Cited by 7
Proximity Binding Assay for PROTAC Ternary Complex Analysis
Ponzo, I., Soldà, A., Crowe, C., Dahl, G., Jahodová, T., Heerwig, A., Geschwindner, S., Ciulli, A., & Rant, U. (2026) · ACS Sensors · doi:10.1021/acssensors.5c04944 · Cited by 7
Self-citationStacey, P., Lithgow, H., Lewell, X. Q., Konopacka, A., Besley, S., Green, G., Whatling, R., Law, R. P., Röth, S., Sapkota, G. P., et al. (2021) · SLAS DISCOVERY · doi:10.1177/24725552211017517 · Cited by 7
Molecular Glue Degraders: From Serendipity to Hunting and Design
Nieto‐Barrado, L., Domostegui, A., & Mayor‐Ruiz, C. (2022) · Wiley eBooks · doi:10.1002/9783527836208.ch6 · Cited by 7
The Therapeutic Potential of Targeting the Chd Protein Family in Cancer
Zhang, M., Wu, K., Zhang, W., Lin, X., Cao, Q., Zhang, L., & Chen, K. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108610 · Cited by 7
Hunter, C. E., Pohl, E., & Freitag, S. (2025) · Biophysical Reviews · doi:10.1007/s12551-025-01359-x · Cited by 7
Getting a Handle on Chemical Probes of Chomatin Readers
Waybright, J. M., & James, L. I. (2020) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0274 · Cited by 7
Torielli, L., Serapian, S. A., Mussolin, L., Moroni, E., & Colombo, G. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c01408 · Cited by 7
Stein, R. R., Fouché, M., Kearns, J. D., & ROTH, H. ‐. (2023) · RSC Chemical Biology · doi:10.1039/d2cb00216g · Cited by 7
Nandy, A. K., Boppana, K., & Phukan, S. (2025) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-025-00630-3 · Cited by 7
Ma, L., Yang, L., Lei, L.-T., Zeng, J., Zhang, J., Qiao, Y., & Wu, Z. (2019) · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy · doi:10.1016/j.saa.2019.117463 · Cited by 7
Beute für das Proteasom: Gezielter Proteinabbau aus medizinalchemischer Perspektive
Luh, L. M., Scheib, U., Juenemann, K., Wortmann, L., Brands, M., & Cromm, P. M. (2020) · Angewandte Chemie · doi:10.1002/ange.202004310 · Cited by 7
Cai, M., Dong, J., Li, H., & Qin, J. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220211091806 · Cited by 7
Major Advances in Emerging Degrader Technologies
Luo, H., Wu, L., He, Y., Qin, C., & Tang, X. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.921958 · Cited by 7
Design and Applications of Bifunctional Small Molecules in Biology
Boyd, S. R., Chang, L., de Rezende, W. C., Raji, I. O., Kandel, P., Holmes, S. L., & Young, D. W. (2020) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2020.140534 · Cited by 7
Exploring DCAF15 for reprogrammable targeted protein degradationPreprint
Coomar, S., & Gillingham, D. G. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/542506 · Cited by 7
Dixon, T., MacPherson, D., Mostofian, B., Dauzhenka, T., Lotz, S., McGee, D., Shechter, S., Shrestha, U. R., Wiewiora, R., McDargh, Z. A., et al. (2021) · doi:10.1101/2021.09.26.461830 · Cited by 7
Biomacromolecule-mediated targeted protein degradation: an emerging strategy for cancer therapy
Xi, M., Zhang, F., Zhu, J., Shen, H., Wu, C., Gao, X., Wu, Y., Wu, Y., Shen, R., & Xia, G. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118019 · Cited by 6
Montisci, F., Friggeri, L., Burusco, K. K., McCabe, P., Popovic, B., & Cole, J. C. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5c00880 · Cited by 6
Branching beyond bifunctional linkers: synthesis of macrocyclic and trivalent PROTACs
Cao, Y., Harris, A. L., & Ciulli, A. (2025) · Nature Protocols · doi:10.1038/s41596-025-01283-0 · Cited by 6
Self-citationLu, X., & Hu, Q. (2026) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6c00029 · Cited by 6
Methods to Study the Molecular Mechanism and Drive the Design of Protein Degraders
Crowe, C., & Ciulli, A. (2026) · Chemical Reviews · doi:10.1021/acs.chemrev.5c00800 · Cited by 6
Self-citationLinkerology in PROTACs: learnings for proximity-inducing therapeutics
Prieto‐Díaz, R., Urbina, A., Rodriguez-Rios, M., & Ciulli, A. (2026) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2026.07.004 · Cited by 7
Self-citationSolid‐Phase Synthesis of PROTACs and SNIPERs on Backbone Amide Linked (BAL) Resin
Hales, L. T., & Thompson, P. E. (2023) · Chemistry - A European Journal · doi:10.1002/chem.202301975 · Cited by 6
Reevaluation of bromodomain ligands targeting BAZ2A
Cazzanelli, G., Vedove, A. D., Parolin, E., D’Agostino, V., Unzue, A., Nevado, C., Caflisch, A., & Lolli, G. (2023) · Protein Science · doi:10.1002/pro.4752 · Cited by 6
Monteleone, S., Morao, I., Fedorov, D. G., & Kellici, T. F. (2025) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.4c00534 · Cited by 6
Lin, Y., Liu, J., Tian, X., Wang, J., Su, H., Xiang, J., Cao, T., Wang, Y., Xie, Q., & Yu, X. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117420 · Cited by 6
Murakami, K., Nguyen, T. H. V., Nagao, C., Mizuguchi, K., & Bitan, G. (2025) · JACS Au · doi:10.1021/jacsau.5c00269 · Cited by 6
Characterization of PROTAC specificity and endogenous protein interactomes using ProtacID
Shrestha, S., Maitland, M. E. R., Li, J., Duan, S., Nie, D. Y., St‐Germain, J. R., Kanaris, M., Baršytė-Lovejoy, D., Arrowsmith, C. H., & Raught, B. (2025) · Nature Communications · doi:10.1038/s41467-025-63357-7 · Cited by 7
Linker-Driven Sampling of PROTAC-Induced Ternary Complexes
Zhao, H., Schießer, S., Tyrchan, C., & Czechtizky, W. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00527 · Cited by 6
Targeting MDM2 for the development of a new cancer therapy: progress and challenges
Aguilar, A., Thomas, J. E., & Wang, S. (2023) · Medicinal Chemistry Research · doi:10.1007/s00044-023-03102-1 · Cited by 6
Payne, N. C., Ichikawa, S., Woo, C. M., & Mazitschek, R. (2024) · STAR Protocols · doi:10.1016/j.xpro.2024.103129 · Cited by 7
Synthesis and evaluation of chemical linchpins for highly selective CK2α targeting
Greco, F., Krämer, A., Wahl, L. M., Elson, L., Ehret, T. A. L., Gerninghaus, J., Möckel, J., Müller, S., Hanke, T., & Knapp, S. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116672 · Cited by 6
Lind, J., Aksoy, O., Prchal‐Murphy, M., Fan, F., Fulciniti, M., Stoiber, D., Bakiri, L., Wagner, E. F., Zwickl-Traxler, E., Sattler, M., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01117-4 · Cited by 6
Discovery of Potent, Highly Selective, and Efficacious SMARCA2 Degraders
Li, Z., Harikrishnan, L. S., Xu, G., Samanta, D., Clemente, J. C., Leng, L., Tu, W., Yang, L., Huang, L., Wang, M., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01878 · Cited by 6
PROTAC-mediated Target Degradation: A Paradigm Changer in Drug Discovery?
Cromm, P. M., Crews, C. M., & Weinmann, H. (2020) · Royal Society of Chemistry eBooks · doi:10.1039/9781839160691-00001 · Cited by 6
Discovery and Characterisation of Highly Cooperative FAK‐Degrading PROTACs
Law, R. P., Nunes, J., Chung, C., Bantscheff, M., Buda, K., Dai, H., Evans, J. P., Flinders, A., Klimaszewska, D., Lewis, A. J., et al. (2021) · Angewandte Chemie · doi:10.1002/ange.202109237 · Cited by 6
Li, J., Zhu, R. Y., Zhuang, X., Zhang, C., Shen, H., Wu, X., Zhang, M., Huang, C., Xiang, Q., Zhao, L., et al. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106495 · Cited by 6
From Degraders to Molecular Glues: New Ways of Breaking Down Disease‐Associated Proteins
Nagel, Y. A., Britschgi, A., & Ricci, A. (2021) · Wiley eBooks · doi:10.1002/9783527826872.ch2 · Cited by 6
Multifaceted regulation of enhancers in cancer
Xiao, Q., Xiao, Y., Li, L., Chen, M., & Wu, M. (2022) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2022.194839 · Cited by 6
Linkers for protein degradation
Chamberlain, P. P. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0057-9 · Cited by 6
Roatsch, M., Vogelmann, A., Herp, D., Jung, M., & Olsen, C. A. (2020) · ChemRxiv · doi:10.26434/chemrxiv.12416303 · Cited by 6
Zhang, L., Zhang, S., Zhang, Y., Liu, B., Li, X., & Han, B. (2024) · ChemBioChem · doi:10.1002/cbic.202400837 · Cited by 6
Shcherbakov, A. A., Poppe, L., & Vaish, A. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00652 · Cited by 5
Generating Surprisingly Powerful Pharmacology from Chemically Induced Protein Interactions
Hinshaw, S. M., Banik, S. M., & Gray, N. S. (2025) · Accounts of Chemical Research · doi:10.1021/acs.accounts.5c00225 · Cited by 5
Dynamic characteristics of proteolysis-targeting chimera systems revealed by in silico computations
Xu, K., Ge, J., Tang, R., Hou, T., & Sun, H. (2025) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2025.103151 · Cited by 5
Nanotechnology-based strategies for overcoming clinical limitations of PROTACs in cancer therapy
Cho, H., Kim, J., Lee, H.-Y., Kang, H., & Kim, K. (2025) · Journal of Materials Chemistry B · doi:10.1039/d5tb01162k · Cited by 5
Harnessing Chimeric Degrader Technologies for Antimicrobial Innovation
Poddar, S. K., Dey, K., & Zheng, G. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01479 · Cited by 5
Targeted degradation of BRD4 by PROTACs: advances in cancer therapy
Hong, Y., Liu, X., Li, Y., Yu, M., Wang, C., Nie, C., & Xu, S. (2026) · Chemical Communications · doi:10.1039/d5cc05563f · Cited by 5
Guo, S., Liu, J., Zheng, H., & Wu, X. (2026) · Biomedicines · doi:10.3390/biomedicines14040835 · Cited by 5
Targeted degradation of c-Myc through the midnolin–proteasome pathway
Zhao, J., Wu, H., Yu, H., Li, C., Mao, Y., Yuan, H., & Li, S. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2520128123 · Cited by 5
Engineering Polymeric Nano-PROTAC for Targeted Protein Degradation and Cancer Therapy
Saeed, M., Amina, Z., Xu, Z., & Yu, H. (2026) · Polymer science & technology. · doi:10.1021/polymscitech.5c00122 · Cited by 5
Schulz, J. M., Reynolds, R. C., & Schürer, S. C. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119038 · Cited by 5
Advancing PROTAC therapeutics through chemistry-guided design of smart delivery systems
Yao, T., Zhou, Z., Wang, G., Zhu, Z.-Y., & Li, X.-N. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-026-01853-2 · Cited by 5
Awadasseid, A., Wang, R., Sun, S., Zhang, F., Wu, Y., & Zhang, W. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116257 · Cited by 5
Leveraging Covalency to Stabilize Ternary Complex Formation For Cell–Cell “Induced Proximity”
Krygier, K., Wijetunge, A. N., Srayeddin, A., McCann, H. M., & Rullo, A. F. (2024) · ACS Chemical Biology · doi:10.1021/acschembio.4c00286 · Cited by 5
Wang, Y., He, Y., You, Q., & Wang, L. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104194 · Cited by 5
Drug screening approaches for small-molecule compounds in cancer-targeted therapy
Zhao, Y., Yuan, C., Shi, Y., Liu, X., Luo, L., Zhang, L., Pešić, M., Yao, H.-J., & Li, L. (2024) · Journal of drug targeting · doi:10.1080/1061186x.2024.2427185 · Cited by 5
Development of novel paullone-based PROTACs as anticancer agents
Manda, S., Chatakonda, V. K., Ugale, V. G., Tanwar, S., Raperthi, C., Borkar, M. R., Nale, P. E., Pasikanti, S., & Reddy, P. N. (2024) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2024.141273 · Cited by 5
Discovery of First-in-Class BAZ2A/B and BAZ2B-Selective Degraders
Palaferri, L., Cheng‐Sánchez, I., Gosselé, K. A., Zielińska, D., & Nevado, C. (2025) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.4c00334 · Cited by 5
Illuminating ubiquitination mechanisms: How cryo-EM has shed light on Cullin RING E3 ligase function
Rizvi, Z., & Lander, G. C. (2025) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2025.103055 · Cited by 5
Zhai, J., Li, C., Wang, S., Sun, B., Cui, Y., Gao, Q., & Sang, F. (2022) · ChemistrySelect · doi:10.1002/slct.202203463 · Cited by 5
E3 ubiquitin ligases in lung cancer: Emerging insights and therapeutic opportunities
Basu, B., Kal, S., Karmakar, S., Basu, M., & Ghosh, M. K. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122333 · Cited by 5
Structure-Based Design of CBP/EP300 Degraders: When Cooperativity Overcomes Affinity
Cheng‐Sánchez, I., Gosselé, K. A., Palaferri, L., Laul, E., Riccabella, G., Bedi, R. K., Li, Y., Müller, A., Corbeski, I., Caflisch, A., et al. (2024) · JACS Au · doi:10.1021/jacsau.4c00292 · Cited by 5
BRDT Inhibitors for Male Contraceptive Drug Discovery: Current Status
Miao, Z., Guan, X., Jiang, J., & Georg, G. I. (2018) · Springer eBooks · doi:10.1007/978-981-13-0773-7_11 · Cited by 5
Sun, J., Shi, F., & Yang, N. (2019) · ACS Omega · doi:10.1021/acsomega.9b01842 · Cited by 5
Fluorophosphonate‐Based Degrader Identifies Degradable Serine Hydrolases by Quantitative Proteomics
Field, S. D., Lee, W., Dutra, J. K., Serneo, F. F., Oyer, J. A., Xu, H., Johnson, D. S., Ende, C. W. A., & Seneviratne, U. I. (2020) · ChemBioChem · doi:10.1002/cbic.202000253 · Cited by 5
CAND1 inhibits Cullin-2-RING ubiquitin ligases for enhanced substrate specificity
Wang, K., Diaz, S., Li, L., Lohman, J. R., & Liu, X. (2024) · Nature Structural & Molecular Biology · doi:10.1038/s41594-023-01167-5 · Cited by 5
The Advent of Directed Protein Degraders in Drug Discovery
Benchekroun, M. (2019) · Future Drug Discovery · doi:10.4155/fdd-2019-0019 · Cited by 5
Adhikari, B., Schneider, K., Diebold, M., Sotriffer, C., & Wolf, E. (2024) · eLife · doi:10.7554/elife.98450 · Cited by 4
MYCN as an oncogene in pediatric brain tumors
Garcia, A. F., Jackson, J., Iyer, P., Oliver, E. G., & Funato, K. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1584978 · Cited by 4
Shotgun Approach for PROTAC Ternary Complex Modeling and Evaluation
Zhao, T., & Gao, Y. Q. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5c02037 · Cited by 4
Kumar, H., & Sobhia, M. E. (2026) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.5c07053 · Cited by 4
PROTACs in targeted protein degradation: Advances in development and AI-enhanced drug discovery
Du, M., Liu, T., Wang, W., Fan, S., Tian, M., Du, Q., Wang, Z., Li, X., Liu, X., Xia, Q., et al. (2026) · European Journal of Medicinal Chemistry Reports · doi:10.1016/j.ejmcr.2026.100332 · Cited by 4
Mechanisms and Design Principles of Proteolysis-Targeting Chimeras and Their Emerging Applications
Knoll, N., Neamati, N., & Üren, A. (2026) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00730 · Cited by 5
Sung, J., Seo, Y., & Lee, J.-Y. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.05.031 · Cited by 4
Targeted delivery of proteolysis-targeting chimeras (PROTAC) and molecular glue degraders (MGD)
Banerjee, M., Detappe, A., & Lammers, T. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115922 · Cited by 4
The Role of Deubiquitinating Enzymes in Primary Bone Cancer
Colaco, J. C., Suresh, B., Kaushal, K., Singh, V., & Ramakrishna, S. (2024) · Molecular Biotechnology · doi:10.1007/s12033-024-01254-y · Cited by 4
Synthesis of selective BCL-XL PROTAC and potent antitumor activity in glioblastoma
Liu, M., Sun, B., Niu, R., Zhang, Y., Li, X., Wang, J., Wang, X., & Yin, J. (2025) · Cell Reports Physical Science · doi:10.1016/j.xcrp.2025.102593 · Cited by 4
Targeted Protein Degradation in Lung Cancer: The Emerging Role of PROTAC Technology and E3 Ligases
Hussain, M. S., Babu, M. A., Afzal, M., Roopashree, R., Lal, M., Rekha, A., Oliver, B. G. G., MacLoughlin, R. J., Chakraborty, A., Dua, K., et al. (2025) · Current Medicinal Chemistry · doi:10.2174/0109298673382742250619055201 · Cited by 4
Yamada, K., Yamanaka, S., Yamakoshi, H., Kohyama, A., Iwabuchi, Y., Kosako, H., & Sawasaki, T. (2025) · Communications Biology · doi:10.1038/s42003-025-08761-x · Cited by 5
Bhusal, S., & Valsson, Ó. (2025) · Physical Chemistry Chemical Physics · doi:10.1039/d5cp02530c · Cited by 4
Computational Modeling of PROTAC Ternary Complexes and Linker Design
Miller, S. A., Andrianov, G. V., Mischley, V., Wharton, K. A., Chen, J. J., & Karanicolas, J. (2022) · Wiley eBooks · doi:10.1002/9783527836208.ch5 · Cited by 4
Chemical rewiring of ubiquitination by degraders and their selectivity routes
Whelan, R., & Mayor‐Ruiz, C. (2024) · Nature Structural & Molecular Biology · doi:10.1038/s41594-024-01215-8 · Cited by 4
PROTAC® technology and potential for its application in infection control
Zakharova, M., & Чудинов, М. В. (2024) · Fine Chemical Technologies · doi:10.32362/2410-6593-2024-19-3-214-231 · Cited by 4
Metadata
- Authors
- Gadd, M. S., Testa, A., Lucas, X., Chan, K.-H., Chen, W., Lamont, D. J., Zengerle, M., & Ciulli, A.
- Affiliations
- University of Dundee (GB)
- Corresponding author
- Ciulli, Alessio
- Venue
- Nature Chemical Biology
- Published
- 2017-03-13
- Volume
- 13
- Issue
- 5
- Pages
- 514-521
- ISSN
- 1552-4450 (ISSN-L)
- 1552-4469
- PMC
- PMC5392356
- OpenAlex
- W2597078857
- Cited by
- 1,242
- References
- 60
- Citations by year
- 2026: 173 · 2025: 173 · 2024: 176 · 2023: 159 · 2022: 138 · 2021: 129 · 2020: 133 · 2019: 86 · 2018: 46 · 2017: 26
- FWCI
- 33.34
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Chemical Biology (publishedVersion)
- PubMed (publishedVersion)
- Lancaster EPrints (Lancaster University) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Discovery Research Portal (University of Dundee) (submittedVersion, other-oa)
- Funders
- Wellcome Trust (100476, 094090/Z/10/Z, 094090, 100476/Z/12/Z)
- Diamond Light Source (MX10071)
- European Commission (H2020-MSCA-IF-2014, H2020- MSCA-IF-2015, H2020, 655516, H2020‐MSCA‐IF, H2020-MSCA)
- Directorate for Biological Sciences
- Horizon 2020 Framework Programme (H2020‐MSCAIF‐2014, H2020-MSCA, MSCA-IF-2014, H2020-MSCA-IF-2015)
- Medical Research Council
- Biotechnology and Biological Sciences Research Council (BB/J001201/1, BB/J001201/2)
- H2020 Marie Skłodowska-Curie Actions (H2020-MSCA-IF-2014, H2020-MSCA-IF-2014-655516, H2020, 655516, H2020-MSCA-IF, H2020-MSCA-IF-2015, H2020-MSCA, 806323, H2020-MSCA-IF-2015-806323)
- FP7 Ideas: European Research Council (311460)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- PROTACs, BRD4, VHL E3 ubiquitin ligase, bromodomain, selective protein degradation, crystal structure, ternary complex, structure-based drug design, ubiquitination
- MeSH terms
- Elongin, Bromodomain Containing Proteins, Amino Acid Sequence, Dipeptides, Heterocyclic Compounds, 3-Ring, Humans, Models, Molecular, Nuclear Proteins, Protein Binding, Protein Conformation, Structure-Activity Relationship, Thermodynamics, Transcription Factors, Crystallography, X-Ray, Cell Cycle Proteins, Ubiquitin-Protein Ligases, Multiprotein Complexes, Von Hippel-Lindau Tumor Suppressor Protein, Small Molecule Libraries, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
